MINERAL'NAYa PLOTNOST' KOSTII POKAZATELI KOSTNOGO METABOLIZMAU PATsIENTOV S IDIOPATIChESKIM VARIANTOM TsENTRAL'NOGO NESAKhARNOGO DIABETA (TsND)
https://doi.org/10.14341/osteo200826-9
Abstract
The aim of this study was to assess the biochemical parameters of bone metabolism and the bone mineral density (BMD) in patients with idiopathic variant of CDI, treated with oral desmopressin.
In 24 patients with idiopathic CDI, treated with oral desmopressin and 24 healthy controls we evaluated BMD (analyzer Prodigy, Lunar, DXA), serum osteocalcin (OK) and C-terminal telopeptide of type I collagen (CTx), (ECLIA, Roche Elecsys 1010/2010) as well as calcium total, ionized calcium and alkaline phosphatase (analyzer Hitachi 912, commercial kits Roche). Anterior pituitary dysfunction and concomitant conditions associated with osteoporosis were eliminated on clinical and laboratory basis.
The results showed no significant differences between study groups with the exception for ionized calcium which was higher in the group of CDI (p=0,02).
We were not able to confirm detrimental effects of idiopathic CDI on BMD and biochemical markers of bone metabolism.
References
1. Беневоленская Л. И., Лесняк О. М. Клинические рекомендации. Остеопороз. - М.: ГЭОТАР Медицина, 2005. - 176 с.
2. Рожинская Л. Я. Cистемный остеопороз. Практическое руководство для врачей. - М.: Издатель Мокеев, 2000. - 196 с.
3. Экспрессия AVPR1A., AVPR1b, AVPR2, ATII/AVPRL и OTR в тканях человека и мыши - <http://symatlas.gnf.org> (доступно от 28,08,2008).
4. Эндокринология: национальное руководство / под ред. И. И. Дедова, Г. А. Мельниченко. - М.: ГЭОТАР-Медиа, 2008. - 1072 с.
5. Colucci S., Colaianni G., Mori G., Grano M., Zallone A. Human osteoclasts express oxytocin receptor // Biochem Biophys Res Commun. 2002 Sep 27;297 (3):442-5.
6. Copland J.A., Ives K.L., Simmons D.J., Soloff M.S. Functional oxytocin receptors discovered in human osteoblasts // Endocrinology. 1999 Sep;140 (9):4371-4.
7. Glolde B. New clues into the etiology of osteoporosis: the effects of prostaglandins (E2 and F2 alpha) on bone // Med Hypotheses. 1992 Jun; 38 (2):125-31.
8. Goodfriend T.L., Friedman A.L., Shenker Y. Hormonal regulation of electrolyte and water metabolism. Endocrinology, 5th Edition / Edited by DeGroot L.J. and Jameson J.L. Chapter 133 - Saunders, 2006-4144 p.
9. Kanis J.A., Johnell O., De Laet C., Jonsson B., Oden A., Oglesby A. International variations in hip fracture probabilities: implications for risk assessment // Journal of Bone & Mineral Research 2002: 17; 1237-1244.
10. Lagumdzija A., Bucht E., Stark A., Hulting A.L., Petersson M. Arg-vasopressin increases proliferation of human osteoblastlike cells and decreases production of interleukin-6 and macrophage colony-stimulating factor // Regul Pept. 2004 Sep 15;121 (1-3):41-8.
11. Lagumdzija A., Pernow Y., Bucht E., Gonon A., Petersson M. The effects of arg-vasopressin on osteoblast-like cells in endothelial nitric oxide synthase-knockout mice and their wild type counterparts // Peptides. 2005 Sep; 26 (9):1661-6. Epub 2005 Mar 2.
12. László F.A., Janáky T., Baláspiri L., Morgat J.L. Biological half-life and organ distribution of [3H]1-deamino-8-D-arginine-vasopressin in the rat // J Endocrinol. 1981 Feb;88 (2):181-6.
13. Molnár A.H., Varga C., Janáky T., Tóth G., Tóth G., Farkas J., László F., László F.A. Biological half-life and organ distribution of [3H]8-arginine vasopressin following administration of vasopressin receptor antagonist OPC-31260 // Regul Pept. 2007 Jun 7;141 (1-3):12-8. Epub 2007 Jan 4.
14. Petersson M., Lagumdzija A., Stark A., Bucht E. Oxytocin stimulates proliferation of human osteoblast-like cells // Peptides. 2002 Jun;23 (6):1121-6.
15. Pivonello R., Colao A., Di Somma C., Facciolli G., Klain M., Faggiano A., Salvatore M., Lombardi G. Impairment of bone status in patients with central diabetes insipidus // J Clin Endocrinol Metab. 1998 Jul;83 (7):2275-80.
16. Pivonello R., Faggiano A., Di Somma C., Klain M., Filippella M., Salvatore M., Lombardi G., Colao A. Effect of a short-term treatment with alendronate on bone density and bone markers in patients with central diabetes insipidus. J Clin Endocrinol Metab // 1999 Jul;84 (7):2349-52.
17. Robertson G. L. Diabetes insipidus // Endocrinol Metab Clin North Am. 1995 24:549-572.
18. Smith D., McKenna K., Moore K., Tormey W., Finucane J., Phillips J., Baylis P., Thompson C.J. Baroregulation of vasopressin release in adipsic diabetes insipidus // J Clin Endocrinol Metab. 2002 Oct; 87 (10):4564-8.
19. Thibonnier M., Conarty D.M., Preston J.A., Wilkins P.L., Berti-Mattera L.N., Mattera R. Molecular pharmacology of human vasopressin receptors // Adv Exp Med Biol. 1998;449:251-76.
20. van Baal J., Raber G., de Slegte J., Pieters R., Bindels R.J., Willems P.H. Vasopressin-stimulated Ca2+ reabsorption in rabbit cortical collecting system: effects on cAMP and cytosolic Ca2+ // Pflugers Arch. 1996 Nov-Dec;433 (1-2):109-15.
21. Vrbiková J., Stanická S., Dvoráková K., Hill M., Vondra K., Bendlová B., Stárka L. Metabolic and endocrine effects of treatment with peroral or transdermal oestrogens in conjunction with peroral cyproterone acetate in women with polycystic ovary syndrome // Eur J Endocrinol. 2004 Feb;150 (2):215-23.
22. Wittner M., di Stefano A., Wangemann P., Nitschke R., Greger R., Bailly C., Amiel C., Roinel N., de Rouffignac C. Differential effects of ADH on sodium, chloride, potassium, calcium and magnesium transport in cortical and medullary thick ascending limbs of mouse nephron // Pflugers Arch. 1988 Oct; 412 (5):516-23.
Review
For citations:
PIGAROVA E.A., ROZhINSKAYa L.Ya., SAZONOVA N.I., KOLESNIKOVA G.S. MINERAL'NAYa PLOTNOST' KOSTII POKAZATELI KOSTNOGO METABOLIZMAU PATsIENTOV S IDIOPATIChESKIM VARIANTOM TsENTRAL'NOGO NESAKhARNOGO DIABETA (TsND). Osteoporosis and Bone Diseases. 2008;11(2):6-9. https://doi.org/10.14341/osteo200826-9
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
